Related references
Note: Only part of the references are listed.Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Victor Chien-Chia Wu et al.
JOURNAL OF CANCER (2020)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Non Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis
Yuqing Deng et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer
H.W. Clouston et al.
THROMBOSIS RESEARCH (2016)
Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation
David Conen et al.
JAMA CARDIOLOGY (2016)
Direct Oral Anticoagulants in Patients With VTE and Cancer A Systematic Review and Meta-analysis
Maria Cristina Vedovati et al.
CHEST (2015)
Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database
Cheng-Yang Hsieh et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2015)
Insights Into Onco-Cardiology Atrial Fibrillation in Cancer
Dimitrios Farmakis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Concordance between Patient Self-Reports and Claims Data on Clinical Diagnoses, Medication Use, and Health System Utilization in Taiwan
Chi-Shin Wu et al.
PLOS ONE (2014)
Epidemiology of cancer-associated venous thrombosis
Jasmijn F. Timp et al.
BLOOD (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antithrombotic therapy and survival in patients with malignant disease
A. K. Kakkar et al.
BRITISH JOURNAL OF CANCER (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials
A. Lazo-Langner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The effect of low molecular weight heparin on survival in patients with advanced malignancy
CPW Klerk et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
AK Kakkar et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
MA Hernan et al.
EPIDEMIOLOGY (2000)
Share Paper
